Certara, Inc. provides biosimulation science, technology, and consulting services for Model-Informed Drug Development (MIDD) in the biopharmaceutical and biotech industries. The company offers mechanistic and empirical biosimulation solutions to predict pharmacokinetics and pharmacodynamics, supporting clinical trial design, first-in-human dosing, and drug-drug interaction predictions. Its portfolio includes the Simcyp Simulator for physiologically based pharmacokinetic modeling, CoAuthor regulatory writing software, and the Certara.AI platform for life sciences-specific generative AI applications. Certara also delivers regulatory science services, data standardization, and market access strategies. The company serves biotech firms, large pharmaceutical companies, and contract research organizations across therapeutic areas including oncology, hematology, diabetes, and rare diseases. Certara’s software is used by global regulatory agencies, including the U.S. FDA, Japan’s PMDA, and China’s CDE.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Information Technology Services Homepage certara.com
Sector Technology IR page ir.certara.com
Tags
biosimulation, pharmacokinetics, pharmacodynamics, regulatory science, drug development, pbpk modeling, clinical trial simulation, generative ai, data standardization, market access, Simcyp Simulator, CoAuthor, Certara.AI
Press page —

Metrics

Valuation  
Market cap $ 1.403B
Market cap (USD) $ 1.403B
P/E -920.00
PEG —
P/BV 1.44
P/S 3.52
P/OCF 17.28
P/FCF 17.92
Dividend yield —
Turnover / mcap —
Returns  
ROE -0.15%
ROI -0.12%
ROIC 0.78%
Profit margin -0.38%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 29.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 17
Quality score 16.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 418.838M 385.148M 354.337M 335.644M 286.104M 243.53M
Net profit -1.595M -12.051M -55.357M 14.731M -13.266M -49.397M
Free cash flow 94.565M 78.841M 80.978M 91.113M 59.245M 43.947M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 8.81 10.65 17.59 16.07 28.42 33.72
Price performance 12m -0.17 -0.39 0.09 -0.43 -0.16 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 54.1M 60.2M 72.2M 75.4M 90.6M 94.6M
↳ YoY growth +11.2% +20.1% +4.4% +20.2% +4.4%
↳ 5y CAGR +11.8%
Borrowings, current (USD) — — 4.68M 3.02M 3.02M 3.02M 3M 2.96M
Borrowings, non-current (USD) — — 294M 292M 290M 288M 292M 290M
Lease liabilities (USD) — — 593,000 13.6M 15.1M 11.3M 16.5M 12.4M
Cash and deposits (USD) 12.2M 29.8M 271M 186M 237M 235M 179M 189M
Intangible assets (USD) — — 396M 512M 487M 487M 485M 447M
Right-of-use assets (USD) — — — 12.6M 14.4M 9.6M 13.8M 11.9M
Net debt (borrowings + leases - cash) (USD) — — 27.4M 123M 71.5M 67.6M 133M 116M
Cash flow detail
Operating cash flow (USD) — 38M 44.8M 60.4M 92.5M 82.8M 80.5M 96.3M
Purchases of property, plant and equipment (USD) — -2.11M -863,000 -1.14M -1.43M -1.78M -1.63M -1.76M
Purchases of intangible assets (USD) — -7.41M -7.07M -7.76M -11.1M -13.5M -19.4M -24.8M
Change in receivables (cash effect) (USD) — -1.52M -3.93M -10.1M -15M 152,000 -16.2M 428,000
Change in payables (cash effect) (USD) — 10M 2.38M 1.13M 5.29M -5.61M -4.77M 4.4M
Share buybacks (cash effect) (USD) — -703,000 -1.08M — — 0.00 0.00 -42.6M
Interest paid (cash effect) (USD) — -26.4M -27.6M -14.2M -17.3M -19.1M -22.7M -19.1M
Income taxes paid (cash effect) (USD) — -4.11M -12.3M -8.6M -10.1M -19.3M -14.7M -12.2M
Share-based compensation (USD) — 1.69M 64.5M 29.5M 30.3M 28.3M 34.8M 33.1M
Operating cash flow before change in receivables (USD) — 39.5M 48.7M 70.5M 108M 82.6M 96.7M 95.9M
Free cash flow (OCF - PPE - intangibles) (USD) — 28.5M 36.9M 51.5M 80M 67.4M 59.4M 69.8M
Income detail
Research and development expense (USD) — 11.6M 19.6M 20.4M 28.2M 34.2M 37.1M 41M
↳ 5y CAGR +26.1% +15.9%
Total comprehensive income (USD) — -12.8M -45.5M -15.6M 10.4M -54.7M -17.9M 13.9M
Comprehensive income to owners (USD) — -12.8M -45.5M -15.6M 10.4M -54.7M -17.9M 13.9M
Provision for credit losses (USD) — 10,000 -53,000 130,000 1.07M 684,000 1.46M 1.14M
Credit cost ratio (credit losses / average receivables) (%) — — — 0.2% 1.6% 0.9% 1.8% 1.2%
Reported Mar 1, 2022 Mar 1, 2022 Mar 1, 2022 Mar 1, 2022 Mar 1, 2023 Feb 26, 2026 Feb 26, 2026 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Certara Reports Third Quarter 2026 Financial Results Bull 3 Bear 0 Results

Certara delivers a solid quarter with double-digit software revenue growth

Updates 2026 financial outlook

Appoints Grant Peterson Chief Product Officer

Company to host conference call and webcast today at 8:30 a.m. ET

RADNOR, PA — November 5, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its third quarter 2026 financial results.

Third Quarter Highlights from Continuing Operations:

Financial results of the Regulatory and Medical Writing business are reported as discontinued operations. The discussion in this earnings release presents the results of continuing operations and excludes amounts related to discontinued operations for all periods presented, unless otherwise noted.

•Revenue was $94.9 million, compared to $90.9 million in the third quarter of 2025, representing growth of 4%.

•Software revenue was $48.8 million, compared to $43.8 million in the third quarter of 2025, representing growth of 11%.

•Services revenue was $46.1 million, compared to $47.1 million in the third quarter of 2025, representing a decrease of 2%.

October 26, 2026

PDF Version

RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2026 before market open on Thursday, November 5th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

To listen by phone, investors may dial 800-715-9871 (646-307-1963 for international callers) and enter access code 2208277. The live webcast will be available through the Certara Earnings Webcast link and the Investor Relations section of the Company’s website at ir.certara.com, where a replay will be archived.

About Certara

Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.

Investor Relations and Media Contact:

Jeff Warren and Jay Liu [email protected]

Company Logo

Your Opt Out Preference Signal is Honored

Privacy Preference Center

This website uses cookies, pixels, web beacons and other third-party tracking technologies (“cookies”) to analyze use of our website (including article and video viewership), improve functionality, personalize your experience, and for the other purposes described in our Privacy Policy. By clicking “Accept All Cookies” or customizing use of cookies below, you consent to the setting of the applicable cookies on your device to track your activities for those purposes. For more details on the data we process and how to exercise your rights, and to view information related to required opt-in disclosures, see our Privacy Policy. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details‎

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details‎

Sale of Personal Data, Profiling, and Targeted Advertising

Sale of Personal Data, Profiling, and Targeted Advertising

Third party trackers collect information to use for analytics and to personalize your experience with targeted ads. Under applicable Privacy Regulations, you have the right to opt-out of the sale of your personal data to third parties, of targeted advertising-related processing, and of some types of profiling. You may exercise your rights by using the toggles below. If you opt out, the ads and content that you see may not be as relevant to you. You have the right to opt back in to these categories at any time should you initially choose to opt out, and you may do so using the same toggles provided below. If you choose to opt-in, we may use cookies, pixels, web beacons and other third-party tracking technologies (“cookies”) to analyze use of our website (including article and video viewership), improve functionality, personalize your experience, and for the other purposes described in our Privacy Policy

  • Targeting Cookies

Switch Label

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

  • Performance Cookies

Switch Label

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details‎

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

Certara, Inc. — Regulation FD Disclosure Bull 0 Bear 0 Routine

On August 4, 2026, Certara, Inc. (the “Company”) hosted its second quarter 2026 earnings conference call and posted on its website its second quarter 2026 earnings presentation. On the earnings conference call, there was a misstatement in the spoken reference to the 2025 adjusted EBITDA generated by the Company’s recently divested Regulatory and Medical Writing business, which was quoted as having “generated approximately $17 million of adjusted EBITDA in 2025 excluding unallocated overhead costs” (emphasis added), which should have been quoted as having “generated approximately $17 million of adjusted EBITDA in 2025 including unallocated overhead costs” (emphasis added).

The 2025 adjusted EBITDA generated by the Regulatory and Medical Writing business excluding unallocated corporate expense that will remain with the Company is approximately $23 million.

The second quarter 2026 earnings presentation contained the same misstatement and an updated version of the presentation has been posted to the Company’s website, available at ir.certara.com under the heading “Financials & Filings—Quarterly Results”.

Prompts

Certara, Inc. (ticker CERT), listed in United States.

ETFs Holding Certara, Inc.

ETF Weight in ETF Shares Market value As of
DSMC 0.55% 108,242 $ 708.985K Jun 30, 2026
AFSM 0.24% 30,736 $ 350.083K Nov 16, 2026
DFSV 0.13% 2,928,502 $ 34.849M Nov 12, 2026
SEIS 0.09% 83,260 $ 545.353K Jun 30, 2026
DFAT 0.08% 2,036,270 $ 24.232M Nov 12, 2026
AVSC 0.04% 112,301 $ 1.279M Nov 16, 2026
RESM 0.03% 184 $ 1,205.20 Jun 30, 2026
DFAS 0.01% 346,467 $ 4.123M Nov 12, 2026
DFSU 0.01% 12,956 $ 154.176K Nov 12, 2026
DXUV 0.00% 10,412 $ 123.903K Nov 12, 2026
DFAC 0.00% 138,654 $ 1.65M Nov 12, 2026
DFAU 0.00% 15,218 $ 181.094K Nov 12, 2026
DCOR 0.00% 49,610 $ 590.359K Nov 12, 2026
MSLC 0.00% 2,384 $ 19.763K Aug 31, 2026
DFUS 0.00% 2,612 $ 31.083K Nov 12, 2026